Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2591 total matches.

Durysta - A Bimatoprost Implant for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
(Rhopressa)1 can be added or substituted if IOP fails to reach the target range with a PGA alone.2 Improper ...
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost (Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is also available in 0.01% (Lumigan) and 0.03% (generics) ophthalmic solutions for the same indication and in a 0.03% solution (Latisse, and generics) for eyelash enhancement. Durysta is the first ocular implant to become available in the US for treatment of glaucoma.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):116-7 |  Show IntroductionHide Introduction

Lumateperone (Caplyta) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
, blunted affect).1 Second-generation antipsychotic drugs are generally used for initial treatment ...
The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):113-6 |  Show IntroductionHide Introduction

Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
corticosteroid deflazacort (Emflaza) were approved earlier.1,2 THE DISORDER — DMD is a progressive, X-linked ...
Golodirsen (Vyondys 53 — Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in the ~8% of patients who have mutations of the dystrophin gene that are amenable to exon 53 skipping. It is the first drug to be approved for this indication and the third to be approved for treatment of DMD; the antisense oligonucleotide eteplirsen (Exondys 51) and the oral corticosteroid deflazacort (Emflaza) were approved earlier.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):119-20 |  Show IntroductionHide Introduction

IV Meloxicam (Anjeso) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
in efficacy and safety to other NSAIDs.1 It has COX-2 selectivity in vitro, which decreases at higher ...
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):100-2 |  Show IntroductionHide Introduction

Dapagliflozin (Farxiga) - A New Indication for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
diabetes and established cardiovascular disease (CVD) or multiple cardiovascular risk factors,1,2 has now ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga), which was initially approved by the FDA for treatment of type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular risk factors, has now been approved for a third indication: to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with heart failure with reduced ejection fraction (with or without type 2 diabetes). It is the first SGLT2 inhibitor to...
Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-3 |  Show IntroductionHide Introduction

Melatonin for Insomnia in Children

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
sundown, reaches a peak between 2 AM and 4 AM, and decreases gradually thereafter.1 PRODUCTS — Melatonin ...
Over-the-counter products containing melatonin are widely used as sleep aids in children and adults.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):103-4 |  Show IntroductionHide Introduction

Lemborexant (Dayvigo) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
) was the first.1 Table 1. Pharmacology Class Orexin receptor antagonist Formulation 5, 10 mg tablets Route ...
The FDA has approved lemborexant (Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) was the first.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):97-100 |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
into (or first appearing in) adulthood or even old age.1,2 NONPHARMACOLOGIC THERAPY Skin hydration (a daily ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

Eptinezumab (Vyepti) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
once monthly (fremanezumab can also be given once every 3 months), were approved earlier.1 ...
The FDA has approved eptinezumab-jjmr (Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):85-7 |  Show IntroductionHide Introduction

Talicia - A 3-Drug Combination for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
patient adherence to multidrug regimens.1 When available, susceptibility testing should be used to guide ...
The FDA has approved a fixed-dose combination of omeprazole, amoxicillin, and rifabutin (Talicia – RedHill) for treatment of Helicobacter pylori infection in adults. Talicia is the first rifabutin-based product to be approved for this indication.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-5 |  Show IntroductionHide Introduction